ELISA, Flow Cytometry, Western Blot. This antibody was tested by ELISA and immunoblotting and was found to be reactive with both unphosphorylated and phosphorylated AKT2 in a lysate of HEK293 cells. Although not tested, this antibody is likely functional in immunohistochemistry and immunoprecipitation.This product has been assayed by immunoblot against a HEK293 cell lysate and is reactive at a 1:1,000 dilution showing a band at approximately 60 kDa. A working dilution of 1:4,000 to 1:16,000 is suggested for this product in a standard capture ELISA using TMB (3,3',5,5'-Tetramethylbenizidine) code # TMBE-100 as a substrate for 30 minutes at room temperature against 0.1 ug of the immunizing peptide. Researchers should determine optimal titers for other applications.
Reviews / Ratings
If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
This affinity purified antibody is directed against human AKT2. The antibody detects both unphosphorylated and phosphorylated forms of the protein. The product was affinity purified from monospecific antiserum by immunoaffinity purification. Cross reactivity with AKT2 from other species has not been determined, however, the sequence of the immunogen shows 85% identity to mouse and 92% identity with rat, therefore, cross reactivity is expected.
Immunogen
This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to aa 455-468 (of 481) of human AKT2 conjugated to Keyhole Limpet Hemocyanin (KLH).
Other Names
rabbit anti-AKT2 antibody, AKT 2, AKT-2, PKB antibody, PKB beta antibody, PKBBETA antibody, PRKBB antibody, Protein kinase Akt 2 antibody, Protein kinase B beta antibody, RAC-beta serine/threonine-protein kinase, RAC-PK-beta
Subramanyam M, Takahashi N, Hasegawa Y, et al. Inhibition of protein kinase Akt1 by apoptosis signal-regulating kinase-1 (ASK1) is involved in apoptotic inhibition of regulatory volume increase. J. Biol. Chem. 2010 Feb 26;285(9):6109-6117